Jacobs Levy Equity Management Inc. Grows Position in Humana Inc (NYSE:HUM)

Jacobs Levy Equity Management Inc. increased its holdings in shares of Humana Inc (NYSE:HUM) by 29.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 202,639 shares of the insurance provider’s stock after acquiring an additional 46,381 shares during the quarter. Humana comprises about 0.7% of Jacobs Levy Equity Management Inc.’s investment portfolio, making the stock its 10th largest holding. Jacobs Levy Equity Management Inc. owned approximately 0.15% of Humana worth $53,760,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in HUM. Cornerstone Advisors Inc. increased its holdings in Humana by 13.5% in the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after buying an additional 42 shares during the period. Regentatlantic Capital LLC increased its holdings in Humana by 0.4% in the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after buying an additional 42 shares during the period. Cim Investment Mangement Inc. increased its holdings in Humana by 4.3% in the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock valued at $298,000 after buying an additional 46 shares during the period. Savant Capital LLC increased its holdings in Humana by 2.5% in the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock valued at $522,000 after buying an additional 48 shares during the period. Finally, Greenleaf Trust increased its holdings in Humana by 3.4% in the 2nd quarter. Greenleaf Trust now owns 1,652 shares of the insurance provider’s stock valued at $438,000 after buying an additional 55 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

NYSE:HUM traded up $6.31 during mid-day trading on Friday, hitting $274.69. 916,606 shares of the company’s stock were exchanged, compared to its average volume of 825,326. The company has a 50 day simple moving average of $287.14 and a 200-day simple moving average of $269.22. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The firm has a market capitalization of $37.39 billion, a P/E ratio of 18.88, a PEG ratio of 1.20 and a beta of 0.84.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping the consensus estimate of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.25 billion for the quarter, compared to the consensus estimate of $15.88 billion. During the same period last year, the company earned $3.96 EPS. The firm’s revenue was up 13.9% compared to the same quarter last year. As a group, analysts expect that Humana Inc will post 17.63 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.20 annualized dividend and a yield of 0.80%. Humana’s dividend payout ratio is presently 15.12%.

In related news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.54% of the stock is owned by company insiders.

A number of research firms have recently weighed in on HUM. UBS Group raised their price target on shares of Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Morgan Stanley raised their price target on shares of Humana from $315.00 to $342.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Piper Jaffray Companies raised their price target on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Cantor Fitzgerald upgraded shares of Humana from a “neutral” rating to an “overweight” rating and raised their price target for the company from $300.00 to $345.00 in a research note on Monday, August 12th. Finally, SunTrust Banks raised their price target on shares of Humana to $340.00 and gave the company a “hold” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $341.95.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: Recession

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.